Floatz logo

Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa

Non-Small Cell Lung Carcinoma

Explore 1,128 assets in Non-Small Cell Lung Carcinoma →
Floatz Rating
C39/100
Confidence
Indicative
v0.2
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05088967CT.gov
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
—Terminated———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Non-Small Cell Lung Carcinoma

AssetSponsorPhaseRating
Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa (this asset)Innovent Biologics (Suzhou) Co. Ltd.P1C · 39
NecitumumabJonsson Comprehensive Cancer CenterP3BBB
GlumetinibShanghai JMT-Bio Inc.P3BBB
VeliparibAbbVieP3BBB
d-0316Betta Pharmaceuticals Co., Ltd.P2/3BBB
IcotinibThe First Affiliated Hospital of Guangzhou Medical UniversityP4BBB
ZoledronateChia Tai Tianqing Pharmaceutical Group Co., Ltd.P4BBB
OnartuzumabHoffmann-La RocheP3BBB
AvitinibHangzhou ACEA Pharmaceutical Research Co., Ltd.P3BBB

+42 more in the Non-Small Cell Lung Carcinoma cohort

Other indications for Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa

IndicationSponsorPhaseRating
Cutaneous Melanoma—P1/2CCC · 48
Small Cell Lung Carcinoma—P1CC · 44
Diffuse Large B-Cell Lymphoma—P1CC · 43

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa in Non-Small Cell Lung Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/gamma4-heavy-chain-homo-sapiens-1-446-vh-homo-sapiens-ighv4-3901-960-ighd-ighj302-100-cdr-imgt-10712-26-3553-5998-109-1-120-homo-sapiens-ighg401-ng4ma-ch2-l92-g4v5-h-p10-g4v4-ch2-a13-a12-ch1-121-218-hinge-1-12-s10p-228-219-230-ch2-f13a-234-l12a-235-l92-309-231-340-ch3-341-445-chs-k2del-446-121-446-134-215-disulfide-with-kappa-light-chain-homo-sapiens-1-215-v-kappa-homo-sapiens-igkv1-3301-968-igkj401-100-cdr-imgt6310-27-3250-5289-98-1-108-homo-sapiens-igkc01-100-km3-a451-154-v101-192-109-215-dimer-226-226229-229-bisdisulfide-produced-in-chinese-hamster-ovary-cho-k1sv-cell-line-lacking-the-glutamine-synthetase-gene-gs-ko-glycoform-alfa-non-small-cell-lung-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →